• 1
    Wadden TA, Berkowitz RI, Silvestry F., et al. The fenphen finale: a study of weight loss and valvular heart disease. Obes Res. 1998;6: 27884.
  • 2
    Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337: 5818.
  • 3
    Bowen R., Glicklich A., Khan M., et al. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US. Department of Health and Human Services Interim Public Health Recommendations, November 1997. Morbidity and Mortality Weekly Report. 1997: 46: 10616.
  • 4
    Reid CL, Gardin JM, Yunis C., Kurosaki T., Flack JM. Prevalence and clinical correlates of aortic and mitral regurgitation in a young adult population: the CARDIA study [Ab stract]. Circulation. 1994;90: 1519.
  • 5
    Khan MA, Herzog CA, St. Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1998;339: 7138.